KPTI — Karyopharm Therapeutics Inc. Dilution Risk Tracker

Karyopharm Therapeutics Inc. (KPTI) has a DilutionScore of 74/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

Cash runway is a key watch item: KPTI has approximately 18 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for KPTI in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for KPTI alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.